Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amphastar Pharma (NQ: AMPH ) 47.95 +0.72 (+1.52%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amphastar Pharma < Previous 1 2 3 4 5 6 7 Next > Unlocking the Growth Potential of NASDAQ:AMPH. January 23, 2024 Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. Via Chartmill What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition January 19, 2024 Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion... Via Benzinga Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' January 17, 2024 On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. Via Benzinga NASDAQ:AMPH is not too expensive for the growth it is showing. January 17, 2024 Looking for growth without the hefty price tag? Consider NASDAQ:AMPH. Via Chartmill Cassava Sciences Stock Continues Showing Rising Relative Strength January 16, 2024 Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. Via Investor's Business Daily Why NASDAQ:AMPH is Poised for High Growth. January 16, 2024 Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. Via Chartmill Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. January 02, 2024 Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? Via Chartmill Should you consider NASDAQ:AMPH for growth investing? December 26, 2023 Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? Via Chartmill Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 Via ACCESSWIRE Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study December 28, 2023 On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. Via Investor's Business Daily Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher December 26, 2023 On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. Via Investor's Business Daily Why NASDAQ:AMPH qualifies as a high growth stock. December 12, 2023 Why the growth investor may take a look at AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). Via Chartmill Exploring NASDAQ:AMPH's CANSLIM characteristics. December 05, 2023 Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? Via Chartmill Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). November 21, 2023 Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. Via Chartmill 3 Reasons Why Amphastar Is a Great Growth Stock December 26, 2023 Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great... Via Talk Markets 3 Stocks at the Forefront of Medical Innovation December 25, 2023 Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. Via InvestorPlace Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade December 21, 2023 On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. Via Investor's Business Daily TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating December 07, 2023 TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. Via Investor's Business Daily These Three Biotech Stocks Are Trading At A Discount November 23, 2023 Investors exposed to the biotech sector have seen mixed results this year. Via Talk Markets Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference November 20, 2023 Via ACCESSWIRE Evaluating NASDAQ:AMPH for Growth Investment Opportunities. November 14, 2023 High growth, ROE and relative strength for AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), growth investors may appreciate this. Via Chartmill Recap: Amphastar Pharma Q3 Earnings November 08, 2023 Via Benzinga Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023 November 08, 2023 Via ACCESSWIRE Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade November 10, 2023 Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. Via Investor's Business Daily Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference November 09, 2023 Via ACCESSWIRE 7 Healthcare Stocks That Are Poised to Become the Next Unicorns November 09, 2023 Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. Via InvestorPlace Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday November 09, 2023 U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Earnings Preview For Amphastar Pharma November 07, 2023 Via Benzinga CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade November 08, 2023 On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.